person · Reporting owner

Szyman Catherine M.

Disclosed activity across 4 companies

Tapewire entity: 39015
SEC CIK: 0001438538

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Edwards Lifesciences CorpEW · Entity 3026	CVP, Critical Care	September 03, 2024	September 03, 2024
Outset Medical, Inc.OM · Entity 7026	Director	May 31, 2023	May 31, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Edwards Lifesciences Corp

Report date September 03, 2024 · Filed September 03, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	81,287.4373	Ending reported balance After 2024-09-03 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-09-03 · Grant · Acquired 10,910 · Balance 86,817.4373 F1: These restricted stock units were granted on September 3, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are 100% vested and exercisable on the grant date. Row 2 · 2024-09-03 · Tax withholding · Disposed 5,530 · Balance 81,287.4373

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units were granted on September 3, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are 100% vested and exercisable on the grant date.

Outset Medical, Inc.

Report date May 31, 2023 · Filed May 31, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	24,596	Reported balance After 2023-05-31 transaction · row 1 1 source row Row 1 · 2023-05-31 · Grant · Acquired 7,681 · Balance 24,596 F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Inari Medical, Inc.

Report date February 19, 2025 · Filed February 19, 2025

Section 16 reporting ended · disclosed 2025-02-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-02-19 transaction · row 1 1 source row Row 1 · 2025-02-19 · Other · Disposed 22,429 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.73	Direct	0	Reported balance After 2025-02-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-02-19 · Disposition to issuer · Disposed 49,719 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.

F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

MASIMO CORP

Report date June 10, 2026 · Filed June 12, 2026

Section 16 reporting ended · disclosed 2026-06-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Disposition to issuer · Disposed 7,605 · Balance 0 F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-10 · Disposition to issuer · Disposed 22,283 · Balance 0 F4: Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-06-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-10 · Disposition to issuer · Disposed 6,306 · Balance 0 F5: Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-06-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-10 · Disposition to issuer · Disposed 39,904 · Balance 0 F6: Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $166.52	Direct	Reported balance After 2026-06-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-10 · Disposition to issuer · Disposed 18,617 · Balance 0 F7: On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding. F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
Performance-Based Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-06-10 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-06-10 · Disposition to issuer · Disposed 49,243 · Balance 0 F9: Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance. F8: On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units ("PSUs") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding. F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

Filing footnotes · ownership attribution and instrument terms

F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F2: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration").

F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33).

F4: Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years.

F5: Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years.

F6: Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years.

F7: On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding.

F8: On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units ("PSUs") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding.

F9: Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 15, 2019 Filed Jul 15, 2019 20:53 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	780	$191.70	$149,526.00	Disclosure SEC source: 0001225208-19-010246 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,382.0418 F1 · date: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
July 15, 2019 Filed Jul 15, 2019 20:53 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	372	$191.70	$71,312.40	Disclosure SEC source: 0001225208-19-010246 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,162.0418 F1 · date: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
June 14, 2019 Filed Jun 14, 2019 22:00 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	328	$184.55	$60,532.40	Disclosure SEC source: 0001225208-19-009276 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 990 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse on August 29, 2018. Read SEC document
June 14, 2019 Filed Jun 14, 2019 22:00 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	774	$184.55	$142,841.70	Disclosure SEC source: 0001225208-19-009276 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,475.5729 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
June 14, 2019 Filed Jun 14, 2019 22:00 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	372	$184.55	$68,652.60	Disclosure SEC source: 0001225208-19-009276 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,249.5729 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
May 15, 2019 Filed May 15, 2019 22:57 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	328	$177.92	$58,357.76	Disclosure SEC source: 0001225208-19-008079 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,318 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse on August 29, 2018. Read SEC document
May 15, 2019 Filed May 15, 2019 22:57 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	774	$177.92	$137,710.08	Disclosure SEC source: 0001225208-19-008079 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,621.5729 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
May 15, 2019 Filed May 15, 2019 22:57 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	372	$177.92	$66,186.24	Disclosure SEC source: 0001225208-19-008079 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,395.5729 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
May 14, 2019 Filed May 15, 2019 00:21 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	1,066	$178.17	$189,929.22	Disclosure SEC source: 0001225208-19-008002 · doc4.xml · nonDerivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,767.5729 Read SEC document
May 12, 2019 Filed May 15, 2019 00:21 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionPerformance Rights · Derivative	2,595	$0.00	$0.00	Disclosure SEC source: 0001225208-19-008002 · doc4.xml · derivative · entry 6 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.exercise_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.expiration_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.underlying_shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document
May 12, 2019 Filed May 15, 2019 00:21 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	1,287	$181.10	$233,075.70	Disclosure SEC source: 0001225208-19-008002 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,833.5729 F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document
May 12, 2019 Filed May 15, 2019 00:21 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	682	$181.10	$123,510.20	Disclosure SEC source: 0001225208-19-008002 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,120.5729 Read SEC document
May 12, 2019 Filed May 15, 2019 00:21 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	2,595	$0.00	$0.00	Disclosure SEC source: 0001225208-19-008002 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,802.5729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document
May 08, 2019 Filed May 10, 2019 19:10 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantPerformance Rights · Derivative	2,325	$0.00	$0.00	Disclosure SEC source: 0001223203-19-000028 · primary_doc.xml · derivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,325 Underlying: Common Stock · 2,325 shares Expires 2026-05-07 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document
May 08, 2019 Filed May 10, 2019 19:10 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantEmployee Stock Option (Right to Acquire) · Derivative	16,400	$0.00 Strike: $177.77	$0.00	Disclosure SEC source: 0001223203-19-000028 · primary_doc.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2026-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document
May 08, 2019 Filed May 10, 2019 19:10 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantCommon Stock	1,850	$0.00	$0.00	Disclosure SEC source: 0001223203-19-000028 · primary_doc.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,207.5729 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document
April 15, 2019 Filed Apr 16, 2019 14:57 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	328	$192.00	$62,976.00	Disclosure SEC source: 0001225208-19-006805 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,646 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse on August 29, 2018. Read SEC document
April 15, 2019 Filed Apr 16, 2019 14:57 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	774	$192.00	$148,608.00	Disclosure SEC source: 0001225208-19-006805 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,357.5729 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
April 15, 2019 Filed Apr 16, 2019 14:57 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	372	$192.00	$71,424.00	Disclosure SEC source: 0001225208-19-006805 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,131.5729 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
March 15, 2019 Filed Mar 15, 2019 23:14 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	328	$179.10	$58,744.80	Disclosure SEC source: 0001225208-19-005379 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,974 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse on August 29, 2018. Read SEC document
March 15, 2019 Filed Mar 15, 2019 23:14 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	774	$179.10	$138,623.40	Disclosure SEC source: 0001225208-19-005379 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,455.1517 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
March 15, 2019 Filed Mar 15, 2019 23:14 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	372	$179.10	$66,625.20	Disclosure SEC source: 0001225208-19-005379 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,229.1517 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
February 21, 2019 Filed Feb 22, 2019 02:39 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	328	$176.34	$57,839.52	Disclosure SEC source: 0001225208-19-003318 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,302 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's husband on August 29, 2018. Read SEC document
February 21, 2019 Filed Feb 22, 2019 02:39 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	774	$176.34	$136,487.16	Disclosure SEC source: 0001225208-19-003318 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,601.1517 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
February 21, 2019 Filed Feb 22, 2019 02:39 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	372	$176.34	$65,598.48	Disclosure SEC source: 0001225208-19-003318 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,375.1517 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
February 19, 2019 Filed Feb 20, 2019 01:31 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	2,227	$177.78	$395,916.06	Disclosure SEC source: 0001225208-19-003009 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,747.1517 Read SEC document
February 19, 2019 Filed Feb 20, 2019 01:31 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	697	$177.78	$123,912.66	Disclosure SEC source: 0001225208-19-003009 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,974.1517 Read SEC document
January 15, 2019 Filed Jan 17, 2019 02:05 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	328	$155.00	$50,840.00	Disclosure SEC source: 0001225208-19-000914 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,630 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's husband on August 29, 2018. Read SEC document
January 15, 2019 Filed Jan 17, 2019 02:05 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	372	$155.00	$57,660.00	Disclosure SEC source: 0001225208-19-000914 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,671.1517 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. F2 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document
December 14, 2018 Filed Dec 18, 2018 21:37 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	328	$162.66	$53,352.48	Disclosure SEC source: 0001225208-18-016813 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,958 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's husband on August 29, 2018. Read SEC document
December 14, 2018 Filed Dec 18, 2018 21:37 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	372	$162.66	$60,509.52	Disclosure SEC source: 0001225208-18-016813 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,027.8048 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
November 15, 2018 Filed Nov 15, 2018 22:21 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	328	$147.96	$48,530.88	Disclosure SEC source: 0001225208-18-015564 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,286 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's husband on August 29, 2018. Read SEC document
November 15, 2018 Filed Nov 15, 2018 22:21 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	372	$147.96	$55,041.12	Disclosure SEC source: 0001225208-18-015564 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,399.8048 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
October 15, 2018 Filed Oct 16, 2018 21:15 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	328	$142.64	$46,785.92	Disclosure SEC source: 0001225208-18-014651 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,614 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's husband on August 29, 2018. Read SEC document
October 15, 2018 Filed Oct 16, 2018 21:15 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	372	$142.64	$53,062.08	Disclosure SEC source: 0001225208-18-014651 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,771.8048 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document
May 24, 2018 Filed May 24, 2018 23:59 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	9,815	$139.39	$1,368,112.85	Disclosure SEC source: 0001225208-18-009851 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,001.2313 Read SEC document
May 17, 2018 Filed May 22, 2018 00:44 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantPerformance Rights · Derivative	2,900	$0.00	$0.00	Disclosure SEC source: 0001225208-18-009677 · doc4.xml · derivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,900 Underlying: Common Stock · 2,900 shares Expires 2025-05-16 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. Read SEC document
May 17, 2018 Filed May 22, 2018 00:44 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantEmployee Stock Option (Right to Acquire) · Derivative	20,000	$0.00 Strike: $135.83	$0.00	Disclosure SEC source: 0001225208-18-009677 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-05-16 F2 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document
May 17, 2018 Filed May 22, 2018 00:44 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantCommon Stock	2,325	$0.00	$0.00	Disclosure SEC source: 0001225208-18-009677 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,816.2313 F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document
May 16, 2018 Filed May 19, 2018 00:20 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionPerformance Rights · Derivative	9,362	$0.00	$0.00	Disclosure SEC source: 0001225208-18-009580 · doc4.xml · derivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,362 shares Expires 2018-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · derivative.exercise_date: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · derivative.underlying_shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document
May 16, 2018 Filed May 19, 2018 00:20 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	4,642	$136.43	$633,308.06	Disclosure SEC source: 0001225208-18-009580 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,491.2313 F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document
May 16, 2018 Filed May 19, 2018 00:20 UTC	Edwards Lifesciences Corp EW · Entity 3026	Exercise / conversionCommon Stock	9,362	$0.00	$0.00	Disclosure SEC source: 0001225208-18-009580 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,133.2313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document
May 14, 2018 Filed May 17, 2018 00:53 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	1,066	$138.11	$147,225.26	Disclosure SEC source: 0001225208-18-009495 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,771.2313 F1 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator Read SEC document
February 20, 2018 Filed Feb 22, 2018 23:26 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	2,159	$133.82	$288,917.38	Disclosure SEC source: 0001225208-18-003867 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,773.3446 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document
February 20, 2018 Filed Feb 22, 2018 23:26 UTC	Edwards Lifesciences Corp EW · Entity 3026	Tax withholdingCommon Stock	500	$133.82	$66,910.00	Disclosure SEC source: 0001225208-18-003867 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,932.3446 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document
July 31, 2017 Filed Aug 1, 2017 21:38 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	4,681	$115.78	$541,966.18	Disclosure SEC source: 0001225208-17-013088 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,329.8019 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document
June 29, 2017 Filed Jul 3, 2017 20:08 UTC	Edwards Lifesciences Corp EW · Entity 3026	SaleCommon Stock	4,716	$118.11	$557,006.76	Disclosure SEC source: 0001225208-17-011949 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,921.1453 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document
May 11, 2017 Filed May 15, 2017 21:17 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantPerformance Rights · Derivative	3,400	$0.00	$0.00	Disclosure SEC source: 0001225208-17-009772 · doc4.xml · derivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,400 Underlying: Common Stock · 3,400 shares Expires not disclosed F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document
May 11, 2017 Filed May 15, 2017 21:17 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantEmployee Stock Option (Right to Acquire) · Derivative	24,000	$0.00 Strike: $110.25	$0.00	Disclosure SEC source: 0001225208-17-009772 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2024-05-10 F3 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. F4 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document
May 11, 2017 Filed May 15, 2017 21:17 UTC	Edwards Lifesciences Corp EW · Entity 3026	GrantCommon Stock	2,725	$0.00	$0.00	Disclosure SEC source: 0001225208-17-009772 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care & Vascular 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,528.1453 F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.